AU2007281381A1 - Phytoestrogenic formulations and uses thereof - Google Patents

Phytoestrogenic formulations and uses thereof Download PDF

Info

Publication number
AU2007281381A1
AU2007281381A1 AU2007281381A AU2007281381A AU2007281381A1 AU 2007281381 A1 AU2007281381 A1 AU 2007281381A1 AU 2007281381 A AU2007281381 A AU 2007281381A AU 2007281381 A AU2007281381 A AU 2007281381A AU 2007281381 A1 AU2007281381 A1 AU 2007281381A1
Authority
AU
Australia
Prior art keywords
estrogen
formulation
erp
era
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007281381A
Other languages
English (en)
Inventor
Roberta Diaz Brinton
Liqin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
ROBERTA BRINTON
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ROBERTA BRINTON filed Critical ROBERTA BRINTON
Publication of AU2007281381A1 publication Critical patent/AU2007281381A1/en
Assigned to ZHAO, LIQIN, BRINTON, ROBERTA reassignment ZHAO, LIQIN Alteration of Name(s) of Applicant(s) under S113 Assignors: BRINTON, ROBERTA
Assigned to UNIVERSITY OF SOUTHERN CALIFORNIA reassignment UNIVERSITY OF SOUTHERN CALIFORNIA Request for Assignment Assignors: BRINTON, ROBERTA, ZHAO, LIQIN
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2007281381A 2006-08-02 2007-07-13 Phytoestrogenic formulations and uses thereof Abandoned AU2007281381A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US81984906P 2006-08-02 2006-08-02
US60/819,849 2006-08-02
US88992007P 2007-02-14 2007-02-14
US60/889,920 2007-02-14
US94319007P 2007-06-11 2007-06-11
US60/943,190 2007-06-11
PCT/US2007/073505 WO2008016768A1 (en) 2006-08-02 2007-07-13 Phytoestrogenic formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011236080A Division AU2011236080A1 (en) 2006-08-02 2011-10-17 Phytoestrogenic formulations and uses thereof

Publications (1)

Publication Number Publication Date
AU2007281381A1 true AU2007281381A1 (en) 2008-02-07

Family

ID=38672818

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007281381A Abandoned AU2007281381A1 (en) 2006-08-02 2007-07-13 Phytoestrogenic formulations and uses thereof

Country Status (5)

Country Link
EP (1) EP2046325A1 (ja)
JP (1) JP2009545605A (ja)
AU (1) AU2007281381A1 (ja)
CA (1) CA2659905A1 (ja)
WO (1) WO2008016768A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
US9333192B2 (en) 2010-02-15 2016-05-10 Sinoveda Canada, Inc Phytoestrogen product of red clover and pharmaceutical uses thereof
WO2013050930A1 (en) * 2011-10-02 2013-04-11 Sinoveda Canada, Inc, Development of a red clover phytoestrogen product for the prevention or treatment of osteoporosis
EP3490551A2 (en) * 2016-07-26 2019-06-05 Ausio Pharmaceuticals, LLC Methods of diagnosing and treating alzheimer's disease with s-equol
US10300077B2 (en) * 2016-09-12 2019-05-28 Steven Hoffman Compositions and methods for treating dementia
KR20220043857A (ko) * 2020-09-29 2022-04-05 주식회사 뉴로바이오넷 3-페닐-2h-크로멘 유도체 및 이를 함유하는 알츠하이머의 예방 또는 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2160371A1 (en) * 1993-04-16 1994-10-27 The Trustees Of Tufts College Method for treatment of menopausal and premenstrual symptoms
CA2287965C (en) * 1997-05-01 2009-10-20 Graham Edmund Kelly Treatment or prevention of menopausal symptoms and osteoporosis
EP1163225A1 (en) * 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US20040072765A1 (en) * 1999-04-28 2004-04-15 Novogen Research Pty Ltd. Cardiovascular and bone treatment using isoflavones
AUPQ008399A0 (en) * 1999-04-28 1999-05-27 Novogen Research Pty Ltd Cariovascular applications
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
CA2492754C (en) * 2002-07-24 2018-05-22 Children's Hospital Medical Center Compositions and products containing enantiomeric equol, and methods for their making
US8193240B2 (en) * 2004-03-17 2012-06-05 Nestec S.A. Compositions and methods for reducing or preventing obesity

Also Published As

Publication number Publication date
WO2008016768A1 (en) 2008-02-07
CA2659905A1 (en) 2008-02-07
EP2046325A1 (en) 2009-04-15
WO2008016768A8 (en) 2008-06-12
JP2009545605A (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
US8552057B2 (en) Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases
AU2007281381A1 (en) Phytoestrogenic formulations and uses thereof
US6524616B1 (en) Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
TWI258369B (en) Pharmaceutical compositions of a selective estrogen receptor modulator in combination with sex steroid precursors
Norbury et al. The neuroprotective effects of estrogen on the aging brain
US20040192598A1 (en) Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US20220323464A1 (en) Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
Pratchayasakul et al. Effects of estrogen in preventing neuronal insulin resistance in hippocampus of obese rats are different between genders
Virojchaiwong et al. Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms
Guo et al. Research progress of melatonin (MT) in improving ovarian function: a review of the current status
JP2020520966A (ja) Ｔｒｐｖ１を標的にするミルセン及びカンナビノイド含有組成物
Yu et al. Cycloastragenol prevents age-related bone loss: evidence in d-galactose-treated and aged rats
US8680140B2 (en) Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
Miville-Godbout et al. Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice
Zhao et al. Estrogen receptor β as a therapeutic target for promoting neurogenesis and preventing neurodegeneration
AU2011236080A1 (en) Phytoestrogenic formulations and uses thereof
JP5569949B2 (ja) うつ病を治療するための、選択的セロトニン再取り込み阻害剤およびグルココルチコイド受容体拮抗薬を含む薬物組み合わせ
US20120269793A1 (en) Phytoestrogenic formulations for alleviation or prevention of hair loss
US20110091435A1 (en) Phytoestrogenic formulations for alleviation or prevention of hair loss
Guo et al. Impact of DEHP on mitochondria-associated endoplasmic reticulum membranes and reproductive toxicity in ovary
Zhao et al. ESTROGEN THERAPY FOR PREVENTING ALZHEIMER'S DISEASE: THERAPEUTIC STRATEGIES TO ADDRESS HORMONE THERAPY CHALLENGE FOR THE BRAIN
KR20220054565A (ko) 부틸히드록시아니솔, 부틸히드록시톨루엔 또는 이들의 혼합물을 포함하는 남성 생식기 질환의 예방 또는 치료용 약학적 조성물
AU2011236053B2 (en) Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
Ho The involvement of estrogen receptor (ER) and G protein-coupled estrogen receptor (GPR30) in rapid cellular signaling of phytoestrogens in osteoblasts
Bernardino Evaluation of the antioxidant action of the G protein-coupled estrogen receptor

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITY OF SOUTHERN CALIFORNIA

Free format text: FORMER APPLICANT(S): ZHAO, LIQIN; BRINTON, ROBERTA

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted